Recently, NextSource Pharma’s pricing of Gleostine® (lomustine) was questioned by national media for a series of price increases over the past three years. The subject of drug pricing is an important one. It is more complex than many realize....
Read more
Gleostine® is an FDA-approved chemotherapeutic drug indicated for use in patients with brain tumors, primary and metastatic, following appropriate surgical and/or radiotherapeutics procedures as well with Hodgkin’s lymphoma in combination with other chemotherapies, following disease progression with initial chemotherapy...
Read more
MIAMI, Jan. 20, 2016 /PRNewswire/ -- NextSource Biotechnology, LLC announced today that Gleostine® (lomustine) 5 mg
capsules has been approved by the U.S. Food and Drug Administration (FDA) and is now commercially available in the
United States. Gleostine® is approved...
Read more
MIAMI, Aug. 7, 2014 /PRNewswire/ -- NextSource Biotechnology (NSB) is a leading specialty pharmaceutical manufacturer with a focus on identifying and developing the most viable
pipeline of "matured" and "innovative drugs" in today's global healthcare market.
The product name change from Lomustine (CCNU)...
Read more
MIAMI, Jan. 24, 2014 -- NextSource BioTechnology, LLC, (NSB), an emerging Specialty Pharmaceutical Manufacturing and Marketing Company
focused on Consolidating, Re-Branding and Launching "Matured & Orphan Drugs," has announced its most recent product Lomustine (CCNU)...
Read more
MIAMI, Sept. 23, 2013 -- NextSource Biotechnology, LLC., (NSB), a leading Specialty Pharmaceutical Manufacturing and Marketing company with
a strategic objective of Consolidating, Re-Branding and launching a "Matured & Orphan Drugs" product portfolio in the U.S. and International Healthcare Markets.
Read more